The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Myelodysplastic Syndromes Channel on VJHemOnc is an independent medical education platform, supported with funding from Geron (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2022 | The safety and efficacy of KER-050 for the treatment of patients with lower-risk MDS
Shuh Ying Tan, MBBS, BMedSci, FRACP, FRCPA, St Vincent’s Hospital Melbourne, Melbourne, Australia, discusses the safety and tolerability of KER-050 for the treatment of patients with lower-risk myelodysplastic syndromes (MDS). Dr Tan first highlights the mechanism of action of KER-050, and then goes on to discuss the preliminary results from this Phase II study, which indicated that this agent was well tolerated and demonstrated high efficacy in patients with lower-risk MDS. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
